Lipoinject Small Area 25G is a medical device used for intralipotherapy, a non-surgical method for reducing small, localized pockets of fat in areas such as the chin, arms, knees, and ankles. It is a product of Lipoinject, a leading brand in the field of intralipotherapy needles and syringes.
The Lipoinject Small Area 25G needle is a sterile, single-use device designed to administer the injectable solution directly into the subcutaneous fat layer. It has a 25-gauge needle, which is thinner than the Lipoinject Medium-Large Area 24G needle, making it suitable for treating small areas of fat.
The injection solution used with the Lipoinject Small Area 25G needle is typically a combination of deoxycholic acid and phosphatidylcholine. Deoxycholic acid is a bile acid that helps to break down and absorb fat cells, while phosphatidylcholine is a naturally occurring substance that helps to emulsify and disperse the fat cells.
Intralipotherapy with Lipoinject Small Area 25G is a minimally invasive procedure that is typically performed in a clinic or medical office. Before the treatment, the area to be treated is cleaned and marked, and a topical numbing cream may be applied to reduce discomfort.
The Lipoinject Small Area 25G needle is then used to inject the solution directly into the fat layer, where it works to break down and absorb the fat cells over time. Multiple injections may be required to achieve the desired results.
Patients may experience some swelling, bruising, and discomfort in the treated area after the procedure, but these side effects are typically mild and subside within a few days. Most patients are able to resume their normal activities immediately after the treatment.
Overall, Lipoinject Small Area 25G is a safe and effective method for reducing small pockets of fat in areas that are difficult to target with diet and exercise alone. As with any medical procedure, it is important to consult with a qualified healthcare provider to determine if Lipoinject Small Area 25G is right for you.
There are no reviews yet.